Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01141478 · ClinicalTrials.gov registry record · NA
Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria
A NA study, sponsored by Loma Linda University.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01141478 is a NA study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 8 participants.
The verdict
NCT01141478, a NA study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
Interventions
- DRUG Sorafenib
- RADIATION Proton Beam Radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-09-08 |
| Est. Completion | 2016-06-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01141478
The ClinicalTrials.gov registry entry for NCT01141478 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loma Linda University, which has 237 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sorafenib is the first listed.
NCT01141478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01141478 about?
NCT01141478 is a clinical study titled "Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria". This study is designed to determine whether proton beam radiotherapy plus Sorafenib compared to Sorafenib alone will produce the best results for treating patients with Hepatocellular Carcinoma.
What is the current status of trial NCT01141478?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2010-09-08. Estimated completion is 2016-06-10.
What interventions are being tested in trial NCT01141478?
The interventions under investigation include: Sorafenib (DRUG), Proton Beam Radiotherapy (RADIATION).
Who is sponsoring clinical trial NCT01141478?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.